PROCTER & GAMBLE HEALTH
|
|
BOM : 500126     NSE : PGHL     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
May 17,2024 |
Price(EOD): ₹ 4,788.15
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 7,948.33 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
PROCTER & GAMBLE HEALTH | 1.4% | 2.6% | -0.7% |
SUN PHARMACEUTICAL INDUSTRIES | -0.9% | 0.9% | 62.6% |
CIPLA | 3.5% | 4.2% | 51.8% |
DR REDDYS LABORATORIES | -1% | -2.4% | 28.4% |
ZYDUS LIFESCIENCES | 12.2% | 18% | 103.8% |
DIVIS LABORATORIES | 0.8% | 5.6% | 19.3% |
MANKIND PHARMA | -6.1% | -11.9% | 54.1% |
TORRENT PHARMACEUTICALS | 2.9% | 6.2% | 66.2% |
LUPIN | 1.5% | 4.2% | 109.2% |
FUNDAMENTAL ANALYSIS OF PROCTER & GAMBLE HEALTH
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF PROCTER & GAMBLE HEALTH
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
37.14
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 214.02 Cr
[Latest Qtr - Mar2024 - Standalone Results ] 10.7
P/B Calculated based on Book Value of Rs 743.05 Cr
[Latest Year - Jun2023 - Standalone Results ] 6.8
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Mar2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
25% 38% 22% |
SHARE PRICE MOMENTUM OF PROCTER & GAMBLE HEALTH
PROCTER & GAMBLE HEALTH vs SENSEX
DEBT OF PROCTER & GAMBLE HEALTH
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Jun2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF PROCTER & GAMBLE HEALTH
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF PROCTER & GAMBLE HEALTH
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-18.55% -33.65% -37.1% -35.4% |
-21.33% -15.34% -20.13% -21.34% |
QtrlyTrend |
-8 | |
Latest Qtr: Mar2024 | ||
Quarterly Result Analysis → |
PROCTER & GAMBLE HEALTH related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 4.8% | 5.4% | 60.7% |
S&P BSE 400 MIDSMALLCAP | 4.6% | 5.6% | 57.8% |
S&P BSE MIDSMALLCAP | 4.6% | 5.8% | 62% |
S&P BSE 250 SMALLCAP | 4.6% | 4.5% | 58.3% |
S&P BSE ALLCAP | 3% | 3% | 37% |
You may also like the below Video Courses
FAQ about PROCTER & GAMBLE HEALTH
Is PROCTER & GAMBLE HEALTH good for long term investment?
As on May 17,2024, the Fundamentals of PROCTER & GAMBLE HEALTH look Strong and hence it may be good for long term investment! See Financial Performance of PROCTER & GAMBLE HEALTH . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is PROCTER & GAMBLE HEALTH UnderValued or OverValued?
As on May 17,2024, PROCTER & GAMBLE HEALTH is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of PROCTER & GAMBLE HEALTH ?
As on May 17,2024, the Intrinsic Value of PROCTER & GAMBLE HEALTH is Rs. 3,834.88 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 3,834.88
Fair Value [Median EV / Sales Model] : Rs. 3,482.13
Fair Value [Median Price / Sales Model] : Rs. 3,915.36
Estimated Median Fair Value of PROCTER & GAMBLE HEALTH : Rs. 3,834.88
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.